Figure 3.

Potential future roles of RT in modulating CAR T-cell outcomes. Beyond simple tumor debulking, RT may be utilized in the future at appropriate doses to address tumor-related factors (red background), T-cell factors (orange background), or host factors (blue background) that are operative in driving resistance to CAR T-cells. CAF, cancer associated fibroblasts; MDSC, myeloid derived suppressive cells; RT, radiation therapy; TAM, tumor associated macrophages; TAN, tumor associated neutrophils; Treg, regulatory T-cells.